Lovebuch family happenings

Results from the Cytarabine in early October were just OK. The two main tumors in my abdomen reduced by 50%. I was hoping for more reduction, but so it goes. That meant we needed to move on to next steps. Not much in on the table anymore, but the best drug that we haven’t tried yet was Inotuzumab - ozogamicin, a CD22 immunotherapy drug that has been FDA approved in the last few years to treat refractory ALL.  However it has a major downside, and that the potential of a liver toxicity that would rule out a transplant. The odds of the toxicity with the full dose is about 15%, but it goes up to almost 50% if you have had a prior transplant (which I have). So knowing that, I ruled out full-dose Ino. Dr. Cassaday coincidentally just opened a new clinical trial going that is a dose-escalation for Ino combined with a traditional lymphoma chemo cocktail called EPOCH.  I was patient #1 in the trial. Although being first gave me a little misgivings (is it safe? Does it work?), it also meant I